Related content

Pharmacogenetics of the response to &bgr;β2 agonist drugs: a systematic overview of the field

By Contopoulos-Ioannidis Despina G   Kouri Ioanna   Ioannidis John PA  

Pharmacogenomics, Vol. 8, Iss. 8, 2007-08 ,pp. : 933-958

Future Medicine

Access to resources Recommend Favorite

GRK5 Gln41Leu polymorphism is not associated with sensitivity to &bgr;β₁-adrenergic blockade in humans

By Kurnik Daniel   Cunningham Andrew J   Sofowora Gbenga G   Kohli Utkarsh   Li Chun   Friedman Eitan A   Muszkat Mordechai   Menon Usha B   Wood Alastair JJ   Stein C Michael  

Pharmacogenomics, Vol. 10, Iss. 10, 2009-10 ,pp. : 1581-1587

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of IFN-&bgr;β in multiple sclerosis: towards a personalized medicine approach

By Vosslamber Saskia   van Baarsen Lisa GM   Verweij Cornelis L  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 97-108

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of Antidepressant Drugs: Focus on Key Findings and Future Directions

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 3, 2015-03 ,pp. : 141-147

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics, Regulation and Signaling Pathways of Phase I and II Drug Metabolizing Enzymes

By  

Current Drug Metabolism, Vol. 3, Iss. 5, 2002-10 ,pp. : 481-490

Bentham Science Publishers

Access to resources Recommend Favorite